Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial).
Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA - 021506 and the company will begin distribution in September 2025.
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million*.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
